

# European Respiratory Society Annual Congress 2013

**Abstract Number:** 2202  
**Publication Number:** P3388

**Abstract Group:** 5.1. Airway Pharmacology and Treatment

**Keyword 1:** COPD - management **Keyword 2:** Bronchodilators **Keyword 3:** Quality of life

**Title:** Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials

Dr. Donald 4583 Banerji donald.banerji@novartis.com MD <sup>1</sup>, Dr. Vijay 4584 Alagappan vijay.alagappan@novartis.com MD <sup>1</sup>, Dr. Yulia 4585 Green yulia.green@novartis.com <sup>2</sup>, Dr. Nicola 4586 Gallagher nicola.gallagher@novartis.com <sup>2</sup>, Dr. Angel 4587 FowlerTaylor angel.fowlertaylor@novartis.com <sup>1</sup>, Dr. Peter 4588 D'Andrea peter.dandrea@novartis.com MD <sup>1</sup> and Dr. Hungta 4589 Chen hungta.chen@novartis.com <sup>1</sup>. <sup>1</sup> Primary Care, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States and <sup>2</sup> Primary Care, Novartis Horsham Research Centre, Horsham, United Kingdom .

**Body:** Introduction For effective treatment of patients with COPD it is necessary to improve dyspnea and health status and reduce symptoms and rescue medication use. We present the efficacy of QVA149 on these parameters from the IGNITE program. Methods 4891 patients in the IGNITE trials were assessed. SHINE (N=2144) and ILLUMINATE (N=523) randomized patients with moderate-to-severe COPD to QVA149, indacaterol (IND), glycopyrronium (GLY), placebo (PB) or tiotropium (TIO); salmeterol/fluticasone (SFC) or QVA149 for 26 weeks. SPARK (N=2224) randomized severe-to-very severe COPD patients to QVA149, GLY or TIO for 64 weeks. Results Improvements in Transition Dyspnea Index (TDI) score, and St George's Respiratory Questionnaire (SGRQ) were greater for QVA149 vs. PB, IND, GLY, TIO, and SFC. QVA149 demonstrated reductions in symptoms and rescue medication use relative to all comparators (Table).

Parameter	SHINE				SPARK		ILLUMINATE
	Differences for QVA149 110/50µg vs.						
	PB (N=232)	IND 150µg (N=476)	GLY 50µg (N=473)	TIO 18µg (N=480)	GLY 50µg (N=739)	TIO 18µg (N=737)	SFC 50/500µg (N=264)
TDI score, Wk 26	1.09 <sup>a</sup>	0.26 <sup>b</sup>	0.21 <sup>b</sup>	0.51 <sup>a</sup>	-	-	0.76 <sup>a</sup>
SGRQ total score Wk 26	-3.01 <sup>a</sup>	-1.09 <sup>b</sup>	-1.18 <sup>b</sup>	-2.13	-1.88 <sup>a</sup>	-1.71 <sup>a</sup>	-1.13 <sup>b</sup>
SGRQ total score Wk 64	-	-	-	-	-2.07 <sup>a</sup>	2.69 <sup>a</sup>	-
	0.67 <sup>a</sup>	0.13 <sup>b</sup>	0.26 <sup>a</sup>	0.24 <sup>a</sup>	0.37 <sup>a</sup>	0.44 <sup>a</sup>	0.05 <sup>b</sup>

Mean daily total symptom score							
Rescue medication use (daily no. of puffs)	-0.96 <sup>a</sup>	-0.30 <sup>a</sup>	-0.66 <sup>a</sup>	-0.54 <sup>a</sup>	-0.81 <sup>a</sup>	-0.76 <sup>a</sup>	-0.39 <sup>a</sup>

<sup>a</sup>p<0.05; <sup>b</sup>numerical improvement

Conclusions Results from IGNITE trials show that once-daily QVA149 provides therapeutic benefits by improving dyspnea and health status, and reducing symptoms and rescue medication use.